Research programme: HIV vaccines - VIRxSYS

Drug Profile

Research programme: HIV vaccines - VIRxSYS

Alternative Names: HIV gene therapy vaccine - VIRxSYS; VRX 1116; VRX1023; VRX1273

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator VIRxSYS Corporation
  • Class Gene therapies; Viral vaccines
  • Mechanism of Action HIV envelope protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported HIV infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in HIV-infections in USA (SC, Injection)
  • 18 Jul 2011 Preclinical pharmacodynamics data in HIV infections released by VIRxSYS
  • 09 Dec 2010 Preclinical pharmacodynamics data in HIV infections released by VIRxSYS
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top